pnu 159682

PNU-159682, a metabolite of anthracycline nemorubicin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity.

DMEA-PNU-159682 (molecule D12) is an ADC cytotoxin molecule that includes neomycin (MMDX) metabolites from liver microsomes and the effective ADC cytotoxin PNU-159682.

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which includes metabolites of nemorubicin (MMDX) from liver microsomes and the ADC cytotoxin PNU-159682[1].

Mal-C2-Gly3-EDA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), integrates the cleavable ADC linker Mal-C2-Gly3-EDA with the potent cytotoxin PNU-159682.

Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, DMEA-PNU-159682, is derived from metabolites of nemorubicin (MMDX) found in liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate utilized in antibody-drug conjugate (ADC) therapy. It comprises the ADC linker Mal-Phe-C4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which encompasses metabolites of nemorubicin (MMDX) derived from liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

PNU-159682 carboxylic acid is a potent ADCs cytotoxin,PNU-159682 carboxylic acid has protein fold and diverse functions.

C-lock-G5-DUO-5 is a Drug-linker. DUO-5 is a microtubule inhibitor, a novel toxin molecule with anti-cancer activity. It is connected to C-lock-G5 through a stable covalent irreversible linkage, re-introducing covalent bonding, achieving better stability and improved PK characteristics.

MPB-VC-PAB-DMEA-PNU159682 is a thiol-reactive Drug-linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor, which is commonly used in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG4-VC-PAB-EDA-PNU159682 is a thiol-reactive Drug-linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor and is commonly used in the synthesis of antibody-drug conjugates (ADCs).

MC-VC-PAB-DMEA-PNU159682 is a thiol-reactive Drug-linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor, which is commonly used in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG4-DMEA-PNU159682 is a click-reactive Drug-linker that contains a DBCO group and can undergo strain-promoted acetylene-nitridation cycloaddition reaction (SPAAC) with molecules containing Azide groups. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor with excellent cytotoxicity. DBCO-PEG4-DMEA-PNU159682 can be used in the synthesis of antibody-drug conjugates (ADC).

DBCO-PEG4-GGFG-DMEA-PNU159682 is a click-reactive Drug-linker that contains a DBCO group and can undergo strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing Azide groups. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor. DBCO-PEG4-GGFG-DMEA-PNU159682 can be used in the synthesis of antibody-drug conjugates (ADC).

PNU159682-EDA-Gly3 is a drug linker for antibody-drug conjugates (ADCs), prepared by connecting EDA-Gly3 with a potent DNA topoisomerase II inhibitor PNU159682.

NH2-VC-PAB-DMEA-PNU159682 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor with excellent cytotoxicity, which can be used in the synthesis of antibody-drug conjugates (ADCs).

NH2-PEG3-DMEA-PNU159682 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor with excellent cytotoxicity, which can be used in the synthesis of antibody-drug conjugates (ADCs).

VA-PAB-DMEA-PNU159682 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor with excellent cytotoxicity and can be used in the synthesis of antibody-drug conjugates (ADCs).

PNU159682-EDA-D4 is a deuterium-labeled drug linker used for antibody-drug conjugates (ADCs). It is formed by combining PNU159682-D4 (a potent DNA topoisomerase II inhibitor) with EDA. It is commonly used in the synthesis of ADC compounds. The deuterium labeling can be used as a quantitative tracer during the drug development process.

Mal-VC-PAB-DMEA-PNU-159682 is an agent-linker conjugate for ADCs, designed by linking the topoisomerase II inhibitor PNU-159682 with the lysosomally cleavable dipeptide Mc-VC-PAB, demonstrating potent antitumor activity. Additionally, Mal-VC-PAB-DMEA-PNU-159682 can be utilized for the synthesis of Anti-CD22-NMS249.

Gly2-EDA-PNU is a low-molecular-weight glycinine toxin molecule conjugate used for ADC synthesis. It is composed of the DNA topoisomerase I inhibitor PNU-159682 and the Gly2-EDA linker.

Mal-Val-Ala-PAB(C2-glucuronic acid)-DMEA-PNU-159682 is an active molecule-linker compound used in ADCs, consisting of a cleavable Val-Ala linker and the potent ADC cytotoxin PNU-159682.

Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) is an active molecular conjugate used in antibody-drug conjugates (ADCs), consisting of the ADC linker Mal-N(Me)-C6-N(Me) and the potent cytotoxin PNU-159682. This compound selectively delivers its payload to cells expressing CD46 and releases PNU-159682 through cathepsin B cleavage of the linker, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 has demonstrated sustained tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

Mal-PNU-159682 is a compound classified as an ADC Drug-Linker Conjugate, comprising an ADC linker (maleimide) and the ADC cytotoxin PNU-159682, and it exhibits antitumor activity.

Mal-Val-Ala-amide-(3)PEA-PNU-159682 is a drug-linker conjugate for ADCs, composed of the ADC linker (Mal-Val-Ala-amide-(3)PEA) and the ADC cytotoxin PNU-159682, exhibiting antitumor activity.